title: Use of selective serotonin reuptake inhibitors in the treatment of burning mouth syndrome.
abstract: BACKGROUND
  Patients with burning mouth syndrome (BMS) are frequently treated with antidepressants. Selective serotonin reuptake inhibitors (SSRIs) are increasingly used. Nonetheless, few studies have examined the effects of SSRIs in BMS.
  
  
  OBJECTIVE
  We performed a retrospective study to confirm the need for a prospective study on this topic in the future.
  
  
  METHODS
  51 patients suffering from primary BMS were included in this study.
  
  
  RESULTS
  The frequency of side effects due to SSRIs was low, with mainly digestive side effects. Treatment with SSRIs was more efficient in patients reporting a psychogenic origin for their symptoms. Antidepressants were more frequently stopped when patients did not declare such an origin.
  
  
  CONCLUSIONS
  SSRIs appear to be effective and well tolerated. Declaring a psychogenic component may be considered as a potentiating or predictive factor for the efficacy of treatment with SSRIs. These results should be confirmed by a prospective randomised study.
authors.affiliation: Department of Dermatology, University Hospital of Brest, Brest, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Fleuret
authors.forename: Guy
authors.initials: G
authors.lastname: Le Toux
authors.forename: Jehanne
authors.initials: J
authors.lastname: Morvan
authors.forename: Felipe
authors.initials: F
authors.lastname: Ferreira
authors.forename: Myriam
authors.initials: M
authors.lastname: Chastaing
authors.forename: Gérard
authors.initials: G
authors.lastname: Guillet
authors.forename: Laurent
authors.initials: L
authors.lastname: Misery
mesh_terms: D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002054:Burning Mouth Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors